Franklin Friedman Biography and Net Worth

Director of Deciphera Pharmaceuticals

Mr. Friedman has served as a member of the Board of Directors of Deciphera Pharmaceuticals since November 2019. Mr. Friedman has over 40 years of experience in the professional services industry. Mr. Friedman currently serves as Chief Executive Officer at IPFS Inc., a privately held finance company. Previously, Mr. Friedman worked for Deloitte Touche Tohmatsu Limited (Deloitte), a global services organization, from 1979 until his retirement from Deloitte in November 2019. During this time, Mr. Friedman served in several senior officer positions at Deloitte, including as the global Chief Operating Officer from June 2015 through June 2019; Deloitte’s U.S. Chief Operating Officer, from June 2015 to June 2017; Deloitte’s U.S. Chief Financial Officer, from June 2011 through May 2016, and the Interim U.S. Chief Executive Officer, from 2014 to 2015. Mr. Friedman received his B.A. in Accounting and Business Administration from the University of Kansas.

What is Franklin Stuart Friedman's net worth?: The estimated net worth of Franklin Stuart Friedman is at least $255.90 thousand as of June 8th, 2023. Mr. Friedman owns 10,000 shares of Deciphera Pharmaceuticals stock worth more than $255,900 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Friedman may own. Learn More about Franklin Stuart Friedman's net worth.
How do I contact Franklin Stuart Friedman?: The corporate mailing address for Mr. Friedman and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Franklin Stuart Friedman's contact information.
Has Franklin Stuart Friedman been buying or selling shares of Deciphera Pharmaceuticals?: Franklin Stuart Friedman has not been actively trading shares of Deciphera Pharmaceuticals over the course of the past ninety days. Most recently, on Thursday, June 8th, Franklin Stuart Friedman bought 10,000 shares of Deciphera Pharmaceuticals stock. The stock was acquired at an average cost of $13.88 per share, with a total value of $138,800.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $138,800. Learn More on Franklin Stuart Friedman's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Franklin Friedman (Director), Steven Hoerter (CEO), Thomas Kelly (CFO), Matthew Sherman (EVP), Michael Taylor (Director), and Dennis Walsh (Director). Learn More on Deciphera Pharmaceuticals' active insiders.

Franklin Stuart Friedman Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/8/2023	Buy	10,000	$13.88	$138,800.00	10,000

Franklin Stuart Friedman Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $25.59

$25.59

50 Day Range

MA: $25.59

$25.55

$25.59

2 Week Range

Now: $25.59

$9.90

$25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield